BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12016391)

  • 1. Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast.
    Zhao H; Morimoto T; Sasa M; Tanaka T; Izumi K
    Breast Cancer; 2002; 9(2):118-26. PubMed ID: 12016391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
    Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
    Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-associated biomarker profiles of human breast cancer.
    Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
    Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
    Harbeck N; Thomssen C; Berger U; Ulm K; Kates RE; Höfler H; Jänicke F; Graeff H; Schmitt M
    Breast Cancer Res Treat; 1999 Mar; 54(2):147-57. PubMed ID: 10424405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
    Pusina S
    Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
    Dublin E; Hanby A; Patel NK; Liebman R; Barnes D
    Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis in ductal carcinoma in situ of the breast.
    Moreno A; Figueras A; Lloveras B; Escobedo A; Griera E; Sierra A; Fabra A
    Breast J; 2001; 7(4):245-8. PubMed ID: 11678802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
    Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
    Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
    Descotes F; Riche B; Saez S; De Laroche G; Datchary J; Roy P; André J; Bobin JY
    Clin Breast Cancer; 2008 Apr; 8(2):168-77. PubMed ID: 18621614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Histological grading in ductal carcinoma in situ of the breast].
    Xu W; Zhu X; Zhang T; Tu X; Shi D
    Zhonghua Bing Li Xue Za Zhi; 1999 Oct; 28(5):331-3. PubMed ID: 11869542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.